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Insulin allergy can be successfully 
managed by a systematic approach
Maija Bruun Haastrup1*, Jan Erik Henriksen2, Charlotte Gotthard Mortz3 and Carsten Bindslev‑Jensen3
Abstract 
Background: Type I insulin allergy can be a challenging condition, and there is no international consensus on how 
to establish the diagnosis. Measurement of specific IgE and skin testing have been cornerstones in the diagnostic 
work‑up. However, these tests have limitations, mainly lack of correlation between test results and clinical findings. 
At the Allergy Centre, Odense University Hospital, patients with suspected insulin allergy have been evaluated since 
2003. The aim of this study was to establish a systematic approach to diagnose and treat patients with insulin allergy.
Methods: The study was conducted retrospectively by retrieving data from the Allergy Centre database on patients 
with suspected insulin allergy evaluated from 2003 to 2017. The examination comprised a comprehensive medical 
history, specific IgE against insulin and intracutaneous tests (ICT) with different insulins.
Results: A total of 144 patients were examined on suspicion of insulin allergy of which 110 had negative specific IgE 
in serum. Of the remaining 34 patients, 33 had ICT performed; 2 had negative ICTs, while 31 had one or more posi‑
tive ICT. All 34 patients had mild symptoms, and 4 could obtain symptom relief with antihistamines or local steroids, 9 
could be managed with oral antidiabetics, and 7 were switched to other insulins. The final 14 patients were offered an 
insulin pump because of reactions to many different insulins, many positive ICTs, unmanageable diabetes, young age 
and compliance, or convenience.
Conclusion: Insulin allergy can be managed by a systematic approach, and symptom relief is obtainable in most 
patients.
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Background
Insulin allergy affects 0.1–3% of insulin-treated diabetics 
[1, 2] and causes symptoms ranging from localized itch-
ing and rash to life-threatening anaphylaxis [3–5]. The 
IgE-mediated (type I) reaction is by far the most com-
mon, but type III and type IV reactions have been 
reported as well [1, 6–9].
The diagnosis is based on past and present symptoms 
and signs, together with skin tests and specific immu-
noglobulin E (IgE) measurement in serum. Skin prick 
test (SPT) and intracutaneous test (ICT) have tradition-
ally been used in the evaluation of these patients. How-
ever, the reliability of the results from skin tests has been 
questionable for a number of reasons including false-neg-
ative tests, and non-specific reactions as well as reactions 
to additives (e.g. protamine sulfate) [3, 5, 6, 8–10]. Meas-
urement of specific IgE (sIgE) is another cornerstone in 
the diagnosis, but this method has limitations as well, 
mainly due to poor correlation between clinical findings 
and elevated IgE levels [3, 6]. Consequently, there is no 
consensus on the correct method for diagnosing insulin 
allergy yet, though one was suggested by Jacquier et  al. 
in 2013 [11], based on three patient cases. The authors 
suggested the use of measurement of total IgE, insulin-
specific IgE, and anti-insulin antibodies (IgG) in addition 
to SPT or ICT.
The treatment of insulin allergy is often straightfor-
ward. For many patients it is possible to switch insulin 
preparation or to avoid insulin use by managing their dia-
betes through diet or oral antidiabetics and/or injections 
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with glucagon-like peptide 1 (GLP1) analogue treatment. 
Some patients, however, are insulin dependent and expe-
rience symptoms during treatment with many different 
insulins. These patients are difficult to treat and require 
a more comprehensive approach, sometimes including 
desensitization [3, 9, 12].
At the Allergy Centre at Odense University Hospital 
patients with insulin allergy have been diagnosed and 
treated since 2003. The aim of the present study was to 
summarize the diagnostic findings and to present a sys-
tematic approach for the examination and treatment of 
these patients.
Methods
This study was conducted retrospectively and included 
data from the Allergy Centre database, ACbase, on 
patients seen at the Odense Research Center for Ana-
phylaxis (ORCA), Allergy Centre at Odense University 
Hospital from 2003 through March 2017 with suspi-
cion of insulin allergy. Since 2010 the Allergy Centre in 
Odense has been the only place in Denmark to evaluate 
patients suspected of insulin allergy in collaboration with 
the Department of Endocrinology, Odense University 
Hospital.
The examination comprised a comprehensive medical 
history (type of diabetes, duration and severity of symp-
toms, prior treatment etc.), measurement of specific IgE 
against human, bovine, and porcine insulin and—where 
appropriate—also ICT with different insulins.
Specific IgE measurement (ImmunoCAP) against 
human, bovine and porcine insulin was performed by 
Thermo Fisher, Uppsala Sweden. Values above 0.35 kIU/L 
were considered positive.
Intracutaneous tests were performed by injecting 
20–50  µL of the different insulins in the concentration 
5  IE/mL, and reactions were considered positive if the 
wheal size diameter was 3 mm larger than the initial bleb. 
ICTs were read after 20 min, according to guidelines from 
the European Network on Drug Allergy (ENDA) [13]. As 
controls, skin prick tests were performed with histamine 
10  mg/mL (ALK-Abello, Denmark) as the positive con-
trol and isotonic NaCl as the negative control.
The insulins available for the test varied over time, and 
some of the first patients seen (n = 3) were only tested 
with a selection of the available insulin types, based on 
the clinician’s judgment. The majority, however, were 
tested with the full panel of insulins, which included 
rapid acting human insulin (Humulin  Regular®, Insuman 
 Rapid®,  Actrapid®), rapid acting analogue insulin lispro 
 (Humalog®), and insulin aspart  (NovoRapid®), and inter-
mediate acting isophane human insulin (Humulin  NPH®, 
 Insulatard®, both containing protamine), and long acting 
analogue insulin: Insulin glargine  (Lantus®), and insulin 
detemir  (Levemir®). Most recently, the following addi-
tions have been made to the panel:  Toujeo®,  Abasaglar® 
(both insulin glargine), Tresiba (insulin deglucec), 
 NovoMix® (insulin aspart with added protamine), and 
 Apidra® (insulin glulisine).
SPT with insulin was initially a part of the examination 
but was abandoned due to the poor sensitivity and speci-
ficity of the test. Basophil histamine release (HR test) was 
performed in a few patients but not systematically. Con-
sequently, the results of SPT and HR test are omitted.
The patients—or in the case of children, their parents—
gave informed consent to store their data in the ACbase. 
All data for this study were collected after approval from 
the Danish Data Protection Agency (17/11270).
Results
A flow chart of the protocol for the examination of sus-
pected insulin allergy is presented in Fig. 1.
A total of 144 patients with suspected insulin allergy 
were seen at the Allergy Centre, Odense University Hos-
pital, from 2003 through March 2017. Of these, 34 had 
positive sIgE for insulin and were included in the study 
while 110 had negative sIgE for insulin and were judged 
non-allergic (type I). Among those deemed non-allergic 
71 had an ICT performed with 12 having one or more 
positive ICTs. Another 5 were positive to protamine sul-
fate but none of the included insulins. ICTs were per-
formed in these patients before the results of the IgE 
measurements were available. A positive ICT in a patient 
with a negative IgE may be an unspecific reaction, a reac-
tion to an additive, or a delayed reaction reflecting a type 
IV allergy.
The 34 patients with positive sIgE were categorised 
according to symptom severity. All 34 patients had local 
symptoms only (pruritus, nodules, localised dermati-
tis and infiltration at injection sites). Patients, whose 
symptoms could be alleviated by antihistamines or local 
steroids (n = 4), and patients, who could be managed by 
other antidiabetic medications than insulin (n = 9), were 
treated accordingly.
In 33 of the 34 patients with positive sIgE, ICT was per-
formed. One was not tested due to age (12 years). Two of 
the 33 patients exhibited negative ICTs, however one of 
the two was only tested for one specific insulin prepara-
tion  (Apidra®) due to age (9 years).
The demographics and test results of the 21 insulin 
dependent patients with positive sIgE are presented in 
Table  1 (data not shown for the remaining 13 patients 
because the symptoms of these patients could be man-
aged without insulin). Of the 20 patients tested with ICTs 
19 were ICT-positive for at least one insulin preparation 
(range 1–9). The ICT-negative patient was the 9-year old 
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girl, who was only tested for one insulin preparation by 
ICT.
In the 21 insulin dependent patients a change in treat-
ment regimen was necessary due to symptom severity. 
Where possible (n = 7), a switch was made to another 
insulin preparation. Of these 7 patients, a well-toler-
ated switch had already been made prior to evaluation 
at the Allergy Centre in 4, and consequently, no further 
Paents suspected of insulin allergy (n = 144)
Posive IgE?
No (n = 110)
Yes (n = 34)
Severe symptoms?
No (n = 4) No change in treatment, 
symptom relief if 
necessary 
Not type I allergy
Yes (n = 30)
Need of insulin?
No (n = 9)
Oral andiabecs
Yes (n = 21)
Change of insulin 
possible? Yes (n = 7)
No (n = 14)
Insulin pump
• ≥7 positive ICTs
(n = 7)
• History of 
reactions to many 
insulins (n = 3)
• Unmanageable 
diabetes (n = 1)
• Young age, 
compliance (n = 2)
• Convenience (n = 
1)
Eight of 14 had other 
atopic manifestations/drug 
allergy.
Change of insulin
• Changed prior to 
examination, well 
tolerated (n = 4)
• Changed based on 
ICT results (n = 2)
• Changed despite 
positive ICT, well 
tolerated (n = 1)
None had other atopic 
manifestations/drug allergy.
Fig. 1 Flow chart of the procotol for examination of suspected insulin allergy
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treatment adjustment was needed. Two were success-
fully switched to a different insulin, based on negative 
ICT. The last patient in this group was switched to an 
insulin despite a positive ICT for this particular insulin. 
The switch, however, was well-tolerated.
The final group of patients (n = 14) was offered treat-
ment with an insulin pump in collaboration with the 
Department of Endocrinology, Odense University Hos-
pital. Seven of these patients exhibited ≥ 7 positive 
ICTs. Three additional patients had histories of reac-
tions to many different insulins. One patient’s diabetes 
was unmanageable, two were offered an insulin pump 
because of young age and compliance and one due to 
convenience.
Of the 14 patients given an insulin pump, eight had 
other atopic manifestations or drug allergy (challenge-
verified penicillin allergy, atopic dermatitis, asthma, 
hay fever, contact allergy, and urticaria). None of the 7 
patients, whose insulins were changed, had other atopic 
manifestations/other drug allergies. The groups did not 
differ with regards to age, sex, diabetes type, sIgE levels 
or number of positive ICTs, see Table 2.
Discussion
The majority of the published literature concerning insu-
lin allergy has been case reports or small case series. This 
study is the largest of its kind so far.
Table 1 Demographics and test results
Patients 1–14 were given an insulin pump, 15–21 changed insulin preparation. All symptoms were local. N/A result not available in the database, N/D not done. 
IgE > 0.35 was considered positive
A humulin regular, B insuman rapid, C actrapid, D humulin NPH, E insulatard, F lantus, G levemir, H novorapid, I humalog, J apidra
ID Sex Age DM type sIgE ICT
Porcine Bovine Human A B C D E F G H I J
1 F 60 II 2.1 1.3 1.6 – + – – – – – – – N/D
2 F 55 II 0.6 0.4 0.5 + N/A N/A N/A N/A N/A N/A + + N/D
3 F 14 I 2.6 2.0 1.9 + + – – + + N/D + + N/D
4 F 59 II 7.1 5.9 6.2 + + + + + + + N/D N/D N/D
5 F 41 II 1.5 1.1 1.8 + + + + + + + + + N/D
6 M 55 II 22.8 18.5 22.8 + + + + + + + + + N/D
7 M 67 II 0.6 0.4 0.5 + + + + + + + + – N/D
8 F 47 II 8.9 7.9 7.7 + + + + + + + N/D – N/D
9 M 37 II 0.4 < 0.35 0.4 – + – – – – – – + N/D
10 F 36 I 1.3 1.0 1.0 – – – – – – + – – N/D
11 F 37 II 1.7 1.3 1.6 + + + + + + + + + N/D
12 F 12 I 0.4 < 0.35 < 0.35 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
13 F 9 I 0.5 < 0.35 0.4 N/D N/D N/D N/D N/D N/D N/D N/D N/D –
14 F 54 I 0.1 < 0.35 0.4 – – N/D – – – – + – N/D
15 F 64 I 2.9 2.4 2.7 + + + N/A N/A N/A N/A + + N/D
16 F 46 II 2.5 2.2 2.2 + + + N/D N/D N/D N/D + N/D N/D
17 M 56 II 2.4 2.1 1.8 + + + + + + + + + N/D
18 M 55 I 0.4 < 0.35 0.4 – – – – – – + – – N/D
19 M 30 I 3.4 2.5 2.2 + + + – – + + – + N/D
20 M 57 I 0.6 0.6 0.7 + – + – + – – – – N/D
21 M 79 II 15.0 15.2 13.2 N/D + – + + + + + + N/D
Table 2 Comparison of  patient characteristics and  test 
results between the two groups
Overview of sex distribution and type I/type II diabetes ratio, average age, sIgE 
(human, bovine and porcine) and number of positive ICTs (range). Other atopic 
manifestations/drug allergy: Two patients had challenge-proven penicillin 
allergy, 2 asthma, 2 hay fever, 1 urticaria and 1 atopic dermatitis and contact 
allergy. Only positive sIgE values are included
Insulin pump (n = 14) Other insulin (n = 7)
Sex (M:F) 3:11 5:2
Age (years) 41.6 (9–67) 55.3 (30–79)
Diabetes type (I:II) 4:10 4:3
Other atopic manifesta‑
tions/drug allergy 
(Y:N)
8:6 0:7
No. of positive ICTs 5.9 (0–9) 5 (1–9)
IgEhuman (kIU/L) 4.07 (0.4–22.8) 3.31 (0.4–13.2)
IgEbovine (kIU/L) 4.76 (0.4–18.5) 4.17 (0.6–15.2)
IgEporcine (kIU/L) 3.64 (0.4–22.8) 3.89 (0.4–15.0)
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Of a total of 144 patients suspected of insulin allergy 
only 34 (24%) had positive sIgE, which is comparable to a 
study by Bodtger and Wittrup from 2005 [14], where the 
diagnosis was established in 9 of 22 patients (41%). The 
diagnostic work-up in this study consisted, however, only 
of intracutaneous testing.
We focused mainly on specific IgE measurement for 
the diagnosis of insulin allergy, because this in vitro test 
has a high negative predictive value [10, 15], whereas ele-
vated levels are not necessarily indicative of allergy and 
are thus of limited value without a thorough medical his-
tory and supplementary skin testing [9, 16].
Skin tests, particularly SPT, have poor sensitivity but 
high specificity, and the negative predictive value of ICT 
is high [5, 9, 15]. These tests can be helpful in distinguish-
ing between insulins with and without the capability of 
causing clinical reactions when choosing future treat-
ment for a given patient.
A total of 13 of the 34 patients (38%) with an insulin 
allergy diagnosis in our study could be managed without 
a change in treatment or with oral antidiabetics. Another 
7 were switched to a different insulin preparation, and 
the final 14 were desensitised with continuous subcuta-
neous infusions through an insulin pump. This has been 
described in several reports as an option for patients 
with an indispensable need for insulin who cannot be 
managed by switching to another insulin preparation [8, 
17–22].
The most recent addition to the treatment options for 
these patients is omalizumab. This has been successful 
in two of three case reports so far and may represent an 
interesting alternative for patients whose symptoms can-
not otherwise be managed [23–25].
None of the patients in the present study had a history 
of systemic reactions to insulin. Therefore, other treat-
ment options than desensitization were chosen whenever 
possible. An insulin desensitization was mainly per-
formed in those with many positive ICTs and a history of 
reactions to many different insulin preparations. In case 
of a history of anaphylaxis in insulin dependent patients, 
desensitization should always be performed.
Type 2 diabetics potentially represent a twofold chal-
lenge given that their endogenous insulin production 
decreases with time which most likely will cause a return 
of the symptoms of insulin allergy, when the patients can 
no longer be managed with oral antidiabetics.
Conclusion
Insulin allergy is a challenging condition, but can most 
often be managed by a systematic approach, and symp-
tom relief is obtainable in most if not all patients.
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